Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hein Vincent Stroomberg has a total of 482 co-authors. Here are the top co-authors by number of shared publications:

  • Martin Andreas Røder

    Urological Research Unit, Department of Urology, Centre for Cancer and Organ Diseases, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

    26 shared publications
  • Klaus Brasso

    Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

    15 shared publications
  • Klaus Brasso

    Urological Research Unit, Department of Urology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

    13 shared publications
  • Andreas Røder

    Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

    8 shared publications
  • John Thomas Helgstrand

    Copenhagen Prostate Cancer Center, Department of Urology, Copenhagen University Hospital–Rigshospitalet, Copenhagen, Denmark

    6 shared publications
  • Signe Benzon Larsen

    Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

    5 shared publications

Latest Publications

  • Open Access

    Comparative analysis of surgical outcomes: open versus robot-assisted radical prostatectomy

    by Rikke Groth Olsen, Klaus Brasso, Andreas Røder, Lars Konge, Flemming Bjerrum, Hein Vincent Stroomberg

    Objective: To compare surgical complications, biochemical failure, and mortality rates between open radical prostatectomy (ORP) and robot-assisted radical prostatectomy (RARP). Material and methods: All men undergoing radical prostatectomy (1995–2023) at a single academic hospital were included, and preoperative factors, surgical parameters, complications, biochemical failures, and mortality were collected. Generalized linear models and cause-specific Cox regressions stratified by surgical procedure were used. Cumulative incidences of biochemical failure were estimated with the Aalen-Johansen estimator, accounting for death as a competing risk. Analyses of surgical complications were adjusted for age and lymphadenectomy, while positive surgical margins, biochemical failure, and mortality were adjusted for preoperative PSA, pathological lymph node stage, pT category, tumor percentage, ISUP score, age, and year of surgery. Results: A total of 3,477 men were included (ORP: 1,759; RARP: 1,718). RARP was associated with reduced odds of in-hospital complications (adjusted odds ratio [aOR]: 0.28, 95% confidence interval [CI]: 0.11–0.74). RARP was associated with a reduced risk of biochemical failure compared to ORP (unadjusted hazard ratio [HR]: 0.52, 95% CI: 0.29–0.93). No other outcomes or mortality rates differed significantly. Conclusion: RARP was superior in terms of complications and non-inferior for oncological outcomes compared to ORP at our center. Although the only randomized trial yet, has not proven any significant improvement in long-term cancer control comparing the open versus robotic approach, RARP seems to have replaced ORP as the gold standard for surgical treatment of localized prostate cancer. However, the overall benefit of RARP in the surgical evolution remains elusive.


  • Open Access

    Prostate‐specific antigen testing and prostate cancer‐related outcomes: a Danish nationwide study

    by Frederik K. Palshof, Lina S. Mørch, Klaus Brasso, Niels Kroman, Signe Benzon Larsen, Andreas Røder, Hein V. Stroomberg

    Objective: To assess the prostate‐specific antigen (PSA) testing and prostate cancer‐related outcomes in a national, publicly funded healthcare setting, with recommendations against testing of asymptomatic men. Subjects and Methods: All men born between 1920 and 1970, alive and residing in Denmark on 1 January 2014, were quarried in the national health registries. Age‐standardised rates (ASR) per 100 000 men for men aged >50 years and cumulative incidence at 100 years by Aalen Johansen estimator with delayed entry were estimated for PSA testing, prostate histology, biopsy, prostate cancer diagnosis, and prostate cancer‐specific death. Results: Among 1 371 099 eligible men, the ASR of PSA testing in 2023 was 14 659 tests per 100 000 men (95% confidence interval [CI] 14 585–14 733), and 21 828 tests per 100 000 men (95% CI 21 646–22 111) in men aged 70–79 years. Cumulative incidence at 100 years of a PSA test was 84% (95% CI 84–84%), prostate histology 20% (95% CI 20–20%), biopsy 15% (95% CI 15–15%), prostate cancer diagnosis 12% (95% CI 11–12%), and prostate cancer‐specific death 5.0% (95% CI 5.0–5.1%). The median (interquartile range [IQR]) age at initial PSA test was 60 (52–67) years, 70 (64–76) years at prostate histology and biopsy, 72 (66–78) years at prostate cancer diagnosis, and 84 (78–89) years at prostate cancer‐specific death. Conclusions: In Denmark PSA testing rates are high and prevalent in older ages, despite restrictive national guidelines and active training against PSA testing for general practitioners. The findings support the discussion of whether the availability of the PSA test should be reconsidered to minimise the harms associated with unnecessary testing.


  • Open Access

    Long-term oncological outcomes of pelvic lymph node dissection during radical prostatectomy

    by Rikke Groth Olsen, William Birk Rich, Klaus Brasso, Andreas Røder, Lars Konge, Flemming Bjerrum, Hein Vincent Stroomberg

    Purpose: Lymph node dissection during radical prostatectomy (RP) remains under debate due to an unclear impact on oncological outcomes. Here, we investigate long-term oncological events after RP +/- pelvic lymph node dissection (PLND). Methods: All patients who had an RP from 2006 to 2021 (N=15,515) in the Danish Prostate Registry were included. Cumulative incidence of biochemical failure (BF), subsequent treatment, and prostate cancer-specific death by the Aalen Johansen estimator from the time of RP were compared for men without lymph nodes removed (pNx), without positive lymph nodes (pN0), and with lymph node invasion (pN1). Area under the curve (AUC) of the receiver operating characteristic was used to determine the added value of PLND for outcome discrimination. Results: The 15-year incidences of BF were pNx = 22% (95% confidence interval [95CI]: 20–23), pN0 = 37% (95CI: 35–39), and pN1 = 70% (95CI: 65–76). Fifteen-year incidences of subsequent treatment were 19% (95CI: 18–20), 31% (95CI: 29–33), and 84% (95CI: 79–89) for men with pNx, pN0, and pN1. Fifteen-year risk of prostate cancer-specific death was 2.1% (95CI: 1.6–2.6), 5.5% (95CI: 4.6–6.5), and 25% (95CI: 18–32) for men with pNx, pN0, and pN1. The AUC for the 10-year BF increased from 74% (95CI: 72–77) to 76% (95CI: 73–78) with the addition of pN0/pN1 in the model. The main limitation was the inability to differentiate the number of malignant nodes removed. Conclusion: Men with positive lymph nodes after PLND faced a high risk of BF, subsequent treatment, and prostate cancer-specific death. As the addition of PLND did not substantially improve the discriminative ability, the added benefit of PLND is likely limited. The side effects of PLND should be considered in relation to its possible advantages.


  • The association between lower urinary tract symptoms and urinary tract infections, and subsequent prostate cancer workup: a nationwide population-based case-control study

    by Jeppe Lyngbye Widding, Hein Vincent Stroomberg, Susanne Oksbjerg Dalton, Klaus Brasso, Andreas Røder, Signe Benzon Larsen

    Background We investigated how lower urinary tract symptoms (LUTS) and urinary tract infections (UTIs) affect prostate-specific antigen (PSA) testing and prostate cancer (PCa) workup. Furthermore, we examined the likelihood of high-grade PCa (Gleason score ≥7) and risk factors of high-grade PCa in men with LUTS/UTIs. Methods We identified all men having a first prostate biopsy in Denmark between 2010–2021 and matched with five age-matched controls without a biopsy. LUTS/UTIs was assessed in the year preceding biopsy based on diagnoses and prescriptions obtained from national health registers. Odds ratios (OR) were calculated using crude and multivariable logistic regression models. Results In 63,931 men with a first biopsy, 42% had LUTS/UTIs, compared to 16% of controls. For men with LUTS/UTIs the OR of biopsy was 4.30 (95% CI: 4.22–4.38) and 0.56 (95% CI: 0.54–0.58) for high-grade PCa at biopsy after adjustments, compared to men without LUTS/UTIs. The likelihood of high-grade PCa was significantly higher in men with increasing age, and a Charlson Comorbidity Index ≥2, but not with a known family history of PCa. Conclusion PSA testing in men with LUTS/UTIs increases diagnostic PCa workup, but LUTS/UTIs are not associated with an increased likelihood of high-grade PCa at first biopsy.


  • Open Access

    Early surgical complications following kidney transplantation in adults: A systematic review

    by Milla Ortved, Julia Dagnæs-Hansen, Hein V. Stroomberg, Malene Rohrsted, Søren Schwartz Sørensen, Andreas Røder


  • Open Access

    Prescription patterns demonstrate high demand for treating erectile dysfunction following radical prostatectomy

    by Signe Benzon Larsen, Annika Von Heymann, Hein V. Stroomberg, Anne Sofie Friberg, Klaus Brasso, Andreas Røder, Susanne Oksbjerg Dalton, Randi Karlsen, Pernille Envold Bidstrup, Annamaria Giraldi, et al.

    Background and purpose: Radical prostatectomy can cause erectile dysfunction; however, subsequent treatment with, e.g., phosphodiesterase-5 inhibitors may improve sexual function in the patients. We aim to examine prescriptions for erectile dysfunction after radical prostatectomy and to identify factors that may affect the prescription rate. Patients and methods: A study based on men included in the Danish Prostate Registry (DanProst) in 1995–2021, and information on prescriptions for erectile dysfunction (ATC: G04BE) from the Danish Prescription Registry. We calculated the proportion of prescriptions per month from 1 year before to 2 years after the initial biopsy and odds ratios (ORs) with 95% confidence intervals (CIs) for the risk of having a prescription. Results: We included 9,286 men with radical prostatectomy, 4,221 men managed on active surveillance, and 47,572 men with nonmalignant biopsies for comparison. The proportion of prescriptions increased significantly after biopsy among men with radical prostatectomy compared to men with nonmalignant biopsies and active surveillance. Patients with prior prescriptions for erectile dysfunction had an OR of 3.49 (95% CI, 2.98–4.08) of new prescriptions 6 months after the initial biopsy. Compared to patients treated with bilateral nerve-sparing surgery, patients with unilateral nerve-sparing surgery had an OR of 1.23 (95% CI, 1.06–1.43), whereas patients without nerve-sparing surgery had an OR of 0.40 (95% CI, 0.34–0.46). Interpretation: The observed patterns of prescriptions demonstrate a high demand for the treatment of erectile dysfunction following radical prostatectomy. The group of prostate cancer survivors is large, and, thus, a strong clinical focus on managing erectile dysfunction is needed.


  • Open Access

    Prostate-specific antigen screening at low thresholds of men with pathogenic BRCA1/2 variants

    by Hein V. Stroomberg, Klaus Brasso, Anna A. Blak, Anna Byrjalsen, Thomas van Overeem Hansen, Andreas Røder

    Background: Men with pathogenic BRCA1/2 variants are at higher risk of prostate cancer We included men with likely pathogenic/pathogenic (LP/P) variants in BRCA1/2 in a prostate-specific antigen (PSA) screening program after cascade germline testing since 2014. PSA was tested yearly and an age-specific low PSA threshold for biopsy was used, to determine if a low PSA threshold for biopsy is justified for men with pathogenic BRCA1/2 variants. Methods: From 2014 to 2023 a total of 340 men were included in the program. We report demographics, clinical characteristics, and treatment outcomes at 7 years. Results: The cumulative incidence of a primary biopsy was 37% (95CI: 31‒43) after 7 years. Incidence of prostate cancer diagnosis was 11% (95CI: 7.1‒15). Men referred were 7.8 (95CI: 5.3‒11, p < 0.001) times more likely to be diagnosed with prostate cancer than the general Danish male population. The cumulative incidence of biochemical failure (PSA > = 0.2 ng/ml) 4 years after RP was 22% (95CI: 2.3‒41). The main limitation is that not all men underwent a pre-biopsy MRI. Conclusion: We found a high incidence of prostate cancer in men with LP/P BRCA1/2 variants, but this may be explained by the low PSA threshold for scheduling biopsies. More studies are needed to compare this patient population to men with other germline features. The high risk of recurrence after curative therapy is worrisome and requires further evaluation as to whether this is a biological phenomenon.


  • Open Access

    Introducing robot-assisted kidney transplantation in a high-volume centre in Denmark: a pilot and feasibility study

    by Milla Ortved, Julia Dagnæs-Hansen, Hein V. Stroomberg, Vladimir Karas, Malene Rohrsted, Søren S. Sørensen, Andreas Røder

    Robot-assisted kidney transplantation (RAKT) may reduce surgical complications compared to open kidney transplantation (OKT), but no randomised trials have explored this to date. The aim of the present study is to explore the feasibility of introducing RAKT at our institution, making it available in deceased donor transplantation and evaluate early surgical outcomes prior to performing a randomised trial comparing RAKT to OKT. RAKT was performed at Department of Urology, Copenhagen University Hospital, Rigshospitalet, Denmark. The patients were included from June 2022 until May 2023. The data were collected through the national electronic health records. The data include recipient, donor and intraoperative characteristics, postoperative complications within 90 days graded according to Clavien–Dindo classification and days alive and out of hospital (DAOH). The functional outcomes include eGFR, plasma creatinine, delayed graft function, and rejection episodes. Sixteen RAKTs were performed. Fourteen cases were transplantations with living donors and two cases were with deceased donors. There were no major intra-operative adverse events and no conversions. The median operative time was 223 min and median blood loss 150 ml. The median length of stay was 7 days and median DAOH was 82. Seven complications occurred in five patients at 90 days postoperatively; however, there were no major surgical complications. This study comprehensively assesses patient morbidity following RAKT in a small cohort with results indicating favourable outcomes. This supported our clinical assumption of reduced complications for a randomised trial comparing OKT and RAKT (the ORAKTx trial) which has been initiated (NCT identifier 05730257).


  • Management and Oncologic Outcomes of Incidental Prostate Cancer After Transurethral Resection of the Prostate in Denmark

    by Riccardo Leni, Andrew Julian Vickers, Klaus Brasso, Francesco Montorsi, Alberto Briganti, Torben Kjær Nielsen, Andreas Røder, Hein Vincent Stroomberg

    Approximately 1 in 10 patients without prior prostate biopsy undergoing surgery for lower urinary tract symptoms harbor incidental prostate cancer, however, practice guidelines do not provide recommendations for its management. We aimed at describing the oncologic outcomes of patients with grade group (GG) 1 and 2 prostate cancer diagnosed at transurethral resection of the prostate (TURP). This was a nationwide population-based observational study of patients undergoing TURP in Denmark from 2006 to 2022 using the Danish Prostate Registry. We estimated the cumulative incidence of further biopsies and magnetic resonance imaging (MRI), curative treatment, endocrine treatment, and cause-specific mortality with competing risk analyses. Among 24,494 patients who underwent TURP, there were 1016 men with GG 1 and 381 with GG 2. The 5-year cumulative incidence of further MRIs or biopsies was 36% (95% CI 33%-39%) for GG 1, and 30% (95% CI 25%-34%) for GG 2. Fifteen-year prostate cancer mortality was 8.4% (95% CI 5.3%-11%) for GG 1, and 14% (7.5%-21%) for GG 2. A total of 270 men with GG 1 underwent a biopsy after the TURP, and 162 (60%) had no cancer, in this group, prostate cancer mortality after 15 years was 0.6% (95% CI 0%-1.8%). Men with post-TURP biopsy of GG ≥ 2 had a prostate cancer mortality of 30% (95% CI 9%-50%) 15 years post-TURP. The major limitation was the heterogeneous follow-up, which could lead to an overestimation of prostate cancer mortality compared to a more standardized follow-up. We observed high prostate cancer mortality after TURP with GG 1 or 2, likely due to unsampled high-grade cancer in the peripheral zone. Patients with incidental prostate cancer should be further investigated to rule out high-grade cancer. For patients with GG 1 on TURP, once a subsequent biopsy does not show cancer, follow-up should be lessened similar to that of patients with an initial non-malignant biopsy.